关于雷沙吉兰 ANDANTE 试验
Neuro Congress Offers Array of Studies, Debates
.....关于帕金森症 第一段说：追加的ANDANTE试验表明用雷18周，改善运动症状无严重副作用。（另：TEVA公司认为其有 轻微的 神经保护作用，未获大量支持）第4段说：争论何时考虑DBS。
The conference will feature the first results from the ANDANTE trial of rasagiline (Azilect) as an add-on to dopamine antagonists in Parkinson’s disease patients. The abstract indicated that, compared with placebo, 18 weeks of treatment with rasagiline improved motor symptoms without serious adverse effects.
Another placebo-controlled trial slated for presentation found that the investigational drug pimavanserin, targeting the 5-HT2A serotonin receptor, effectively reduced Parkinson’s disease psychosis. The drug’s manufacturer had announced earlier this year that the trial results were adequate to support an FDA marketing application, but released no specific results.
A third study is expected to report that double vision is common in Parkinson’s disease patients seen in Great Britain, with the prevalence increasing with severity of overall symptoms of the disorder.
Parkinson’s disease is the focus of another debate at the conference -- this one addressing the controversy over when to begin considering deep brain stimulation for managing symptoms.